Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Patent
1991-06-25
1997-05-13
Mosher, Mary E.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
435 792, 436513, 436518, 436813, C12Q 170
Patent
active
056291469
DESCRIPTION:
BRIEF SUMMARY
The invention relates to a method for detection of infection with human papillomavirus (HPV) for diagnostic purposes.
Human papillomavirus (HPV) infection of the cervix uteri is associated with carcinoma of the cervix uteri. Over 50 different HPV types have been identified. HPV types 6, 11, 16, 18, 31, 33 and 51 have been found to infect the genital tract. Types 6 and 11 cause benign proliferative lesions in the genital tract, condylomata acuminata. Types 16, 18, 31 and 33 are found in pre-cancerous lesions and in a majority of carcinomas of the cervix uteri. The human papillomaviruses are immunologically related to the bovine papillomaviruses: antisera reactive with both groups of viruses can readily be prepared. Papillomavirus capsid antigens have been demonstrated in pre-cancerous lesions and condylomatous tissue using such group-specific antisera prepared against viral capsids. Patients with genital warts, cervical intraepithelial neoplasia (CIN) and carcinoma of the cervix uteri have been reported to have higher serum IgG antibody levels to the group-specific capsid antigen compared to control groups.
The object of the invention is to provide a method of the type referred to above in order to facilitate the detection of carcinoma, particularly cervical carcinoma, or pre-stages thereof, or the risk of development of carcinoma.
Another object of the invention is to provide a method of the type referred to above by means of which the presence of carcinoma, or pre-stages thereof, or the risk of development of carcinoma, can be ascertained in a simple and rapid way by detection of the presence of antibodies to human papillomavirus (HPV) in body fluids.
In order to achieve these and other purposes which will be apparent from the description which follows the method of the invention has obtained the characterising features of claims 1, 11 21 and 31.
The invention will be described in more detail below, reference being made to the accompanying drawings in which
FIG. 1 is a graph illustrating the detection of IgA antibodies against papillomavirus in cervical secretions,
FIG. 2 is a graph illustrating the correlation of IgA antibodies to papillomavirus in serums and cervical secretions,
FIG. 3 is a graph illustrating the comparison of IgG antibodies to papillomavirus in serum and vaginal secretions,
FIG. 4 is a graph illustrating the comparison of IgA and IgG antibodies against papillomavirus in vaginal secretions,
FIG. 5 is a are graph illustrating the detection of IgG antibodies by immunoblotting,
FIG. 6 is a graph illustrating the detection of IgA antibodies by immunoblotting,
FIG. 7 is a graph illustrating age and sex-related distribution of serum IgA antibodies to PV in a normal population,
FIG. 8 is a graph illustrating age and sex-related distribution of serum IgG antibodies to PV in a normal population,
FIG. 9 is a graph illustrating detection of IgA antibodies against PV in serum from patients with CIN or carcinoma of the cervix uteri,
FIG. 10 is a graph illustrating detection of IgG antibodies to PV in serum from patients with CIN or carcinoma of the cervix uteri,
FIG. 11 is a graph illustrating detection of IgM antibodies to PV in serum from patients with CIN or carcinoma of the cervix uteri,
FIG. 12 is a graph illustrating the difference between the IgA and IgG response to PV in relation to disease,
FIG. 13 is a graph illustrating IgA reactivity to the L1 protein,
FIG. 14 is a graph illustrating IgA reactivity to the L2 protein,
FIG. 15 is a graph illustrating IgA reactivity to the L1 protein,
FIG. 16 is a graph illustrating IgG reactivity to the L2 protein,
FIG. 17 is a graph, illustrating IgM reactivity to the L1 protein,
FIG. 18 is a graph illustrating IgM reactivity to the L2 protein, and
FIG. 19 is a graph illustrating disease-associated reactivity of synthetic peptides.
Table 1 is a graph tabulating comparisons between IgA and IgG antibodies to PV in serum and cervical secretions.
Table 2 is a graph illustrating detection of cervical carcinoma-associated antibodies.
Table 3 is a graph explaini
REFERENCES:
patent: 4748109 (1988-05-01), Baird
patent: 4777239 (1988-10-01), Schoolnik et al.
Firzlaff, J.M. et al. "Detection of HPV Capsidantigen in Various Squamous Epithelial Lesions using Antibodies Directed against L1 & L2" Virol. 164:467-77 (1988).
Kirsch, I. et al., "Demonstration of SC, IgA, IgG, IgM by Peroxidase--antiperoxidase Technique in Inverted Papillomas of Nasal Cavities", Human Pathol. 15(10):915-20 (1984).
Li et al., Identification of the Human Papillomavirus Type Bb L1 Open Reading Frame Protein in Condylomas and Corresponding Antibodies in Human Sera. Journal of Virology B1(9):2684-2690, 1987.
Li, Chemical Abstracts, 107:130590f, p. 395, 1987.
Medline NLM 87093933 Scand. J. Dent. Res, Oct. 1986, 94(5), pp. 419-426. (Abstract).
Medline NLM 86243722 Breast Cancer Res. Treat. 1986, 7(2), pp. 97-103. (Abstract).
Medline NLM ICDB/85005993 Second General Meeting of the Int. Assoc. or Oral Pathol. Jun. 4-7, 1984, meeting abstract.
Doorbar, Chem. Abstr., vol. 107:130591g, p. 395, Oct. 12, 1987.
Seedorf, Chem. Abstr., vol. 106:132597s, p. 152, Apr. 27, 1987.
Li, Medline File 154, No. 06310140, 1987.
Krisch, Medline File 83, No. 85005364, 1984.
Dillner Joakim
Dillner Lena
Ferring AB
Mosher Mary E.
Wortman Donna C.
LandOfFree
Method for detection of human papillomavirus (HPV) for diagnosti does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for detection of human papillomavirus (HPV) for diagnosti, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for detection of human papillomavirus (HPV) for diagnosti will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1384299